Compounded tirzepatide with cyanocobalamin (vitamin B12) is a pharmacy-prepared injectable that combines tirzepatide, a dual GIP/GLP-1 receptor agonist, with cyanocobalamin, a synthetic form of vitamin B12, in a single formulation. It is not an FDA-approved drug product; it is prepared by compounding pharmacies pursuant to individual prescriptions under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
Among the formulations moving through our platform, tirzepatide with cyanocobalamin ranks as the #3 most-prescribed compounded product on ScriptLinkRx, based on cumulative order volume across clinics ordering through ScriptLinkRx as of mid-2026. That volume, however, sits inside one of the most actively evolving regulatory environments in compounding. Providers considering this formulation need to understand both what the combination is and where FDA currently draws the compliance lines.
What Tirzepatide with B12 Is
Tirzepatide is a synthetic peptide that acts as an agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The FDA-approved versions of tirzepatide are Eli Lilly's Mounjaro (approved in 2022 for type 2 diabetes) and Zepbound (approved in 2023 for chronic weight management). Compounded tirzepatide products are distinct from these approved drugs: they have not undergone FDA premarket review for safety, effectiveness, or quality, and they are not therapeutically interchangeable with the branded products.
Cyanocobalamin is a synthetic, stable form of vitamin B12. FDA-approved cyanocobalamin injection products exist for the treatment of documented B12 deficiency states. In compounded tirzepatide formulations, cyanocobalamin appears as an added ingredient in the same vial — a combination that does not exist in any FDA-approved product. The safety and effectiveness of tirzepatide combined with cyanocobalamin has not been established, a point FDA has made explicitly about GLP-1 formulations containing added vitamins.
How Providers Use It in Practice
Clinics that order compounded tirzepatide with B12 are typically weight-management practices, med spas operating under physician oversight, and metabolic or longevity-focused clinics that run prescriber-supervised programs. In these settings, some providers prescribe combination formulations when they have identified — and documented — a patient-specific clinical reason that an FDA-approved tirzepatide product does not address.
It is worth stating plainly what that documentation burden means: the clinical rationale for including cyanocobalamin must be individualized to the patient, and the responsibility for that justification rests with the prescriber, not the pharmacy. A blanket practice of adding B12 to every tirzepatide prescription, without a patient-specific basis, is precisely the pattern FDA has questioned in its public statements on compounded GLP-1 drugs. Providers should treat the additive as a clinical decision requiring chart support, not a default formulation choice.
Forms and Combinations Available Through Compounding
Compounding pharmacies that prepare tirzepatide-based formulations generally offer them as sterile injectable solutions in multi-dose vials, dispensed with prescriber-directed instructions. Within that category, several variations exist across the market:
- Tirzepatide with cyanocobalamin (B12) — the formulation discussed here.
- Tirzepatide with pyridoxine (B6) — covered in our companion article on compounded tirzepatide with B6.
- Tirzepatide with levocarnitine — see compounded tirzepatide with L-carnitine.
The traditional rationale for compounding — patient-specific customization that an approved product cannot provide — is the legal foundation for all of these. Under section 503A, a compounded drug must be prepared for an identified individual patient based on a valid prescription, and, now that the tirzepatide shortage is resolved, it must not be "essentially a copy" of a commercially available FDA-approved drug. Whether an added ingredient such as cyanocobalamin takes a formulation outside the essentially-a-copy definition depends on whether the prescriber has determined that the change produces a clinical difference for that specific patient. The additive alone does not settle the question.
Clinics ordering these formulations increasingly manage sourcing, prescriber documentation, and pharmacy relationships through dedicated platforms; clinics order compounded medications through platforms like ScriptLinkRx for that reason.
Regulatory Status and Provider Considerations
The regulatory posture of compounded tirzepatide has shifted substantially over the past two years. As of July 2026, the key facts are:
Shortage resolution. FDA removed tirzepatide from the drug shortage list and issued a declaratory order confirming the shortage resolved on December 19, 2024. During the shortage, 503A pharmacies and 503B outsourcing facilities could compound tirzepatide products that were essentially copies of Mounjaro and Zepbound. FDA provided short enforcement-discretion windows after the resolution — ending in February 2025 for 503A pharmacies and March 2025 for 503B outsourcing facilities — after which copy-compounding restrictions applied in full.
Essentially-a-copy restrictions. With the shortage resolved, a 503A pharmacy may compound a tirzepatide formulation only if it is not essentially a copy of the approved products — which, in practical terms, requires a prescriber's documented determination that a modification (such as an added ingredient or a different formulation attribute) produces a significant clinical difference for the identified patient. FDA has publicly noted that some compounders add ingredients such as cyanocobalamin, pyridoxine, levocarnitine, or NAD to GLP-1 formulations, and has stated that the safety and effectiveness of these combinations have not been established. Providers should not assume the presence of B12 immunizes a prescription from copy analysis.
Proposed exclusion from the 503B bulks list. On May 1, 2026, FDA published a Federal Register notice proposing to exclude tirzepatide — along with semaglutide and liraglutide — from the list of bulk drug substances for which there is a clinical need under section 503B. If finalized, outsourcing facilities would not be permitted to compound tirzepatide from bulk API absent a shortage. FDA subsequently extended the comment period on that proposal to July 30, 2026. As of this writing, the proposal is not final, but providers building programs around 503B-sourced tirzepatide should plan for the possibility that this channel narrows.
Not FDA-approved, and not equivalent. No compounded tirzepatide product — with or without B12 — is FDA-approved. FDA has separately reported concerns with compounded GLP-1 products in the market, including dosing errors, unapproved salt forms of active ingredients, and adverse event reports. These concerns underscore why pharmacy selection and formulation verification matter as much as the prescribing decision itself.
State-level considerations. State boards of pharmacy regulate 503A compounding day to day, and several states have taken their own positions on GLP-1 copy compounding. Providers should confirm that any pharmacy partner is licensed in the state where the patient will receive the medication.
Sourcing and Quality: What to Ask a Compounding Pharmacy
Because compounded tirzepatide with B12 does not pass through FDA premarket review, quality assurance shifts to the pharmacy's own practices — and to the diligence of the clinic selecting that pharmacy. Questions worth asking before establishing a relationship:
- API source and documentation. Is the tirzepatide active pharmaceutical ingredient sourced from an FDA-registered facility, and can the pharmacy produce a Certificate of Analysis for each lot of both tirzepatide and cyanocobalamin? Ask specifically whether the API is the base form used in the approved products rather than a salt form, which FDA has flagged as a distinct — and problematic — active ingredient.
- Compounding standards. Does the pharmacy document compliance with USP <797> for sterile compounding (and USP <795>/<800> where applicable)? For 503B outsourcing facilities, ask about current good manufacturing practice (CGMP) compliance and recent FDA inspection history.
- Potency and sterility testing. Is each batch tested for potency, sterility, and endotoxin — and will the pharmacy share the results? Combination formulations add analytical complexity, so ask how the pharmacy verifies the stability of tirzepatide in the presence of cyanocobalamin.
- Beyond-use dating. What beyond-use date is assigned, and is it supported by stability data specific to this combination rather than extrapolated from single-ingredient formulations?
- Licensure and shipment. Is the pharmacy licensed in every state it ships to, and does it use cold-chain shipping validated for peptide products? FDA has received complaints about compounded GLP-1 products arriving outside recommended storage temperatures.
- Copy-compliance process. How does the pharmacy document the prescriber's patient-specific rationale on each prescription? A pharmacy that asks for this documentation is protecting the prescriber as well as itself.
Frequently Asked Questions
Is compounded tirzepatide with B12 FDA-approved?
No. The FDA-approved tirzepatide products are Mounjaro and Zepbound, neither of which contains cyanocobalamin. Compounded formulations are not reviewed by FDA for safety, effectiveness, or quality and are not equivalent to the approved products.
Can 503A pharmacies still compound tirzepatide now that the shortage is over?
Only within the ordinary limits of section 503A. Since the shortage resolution in December 2024 and the expiration of FDA's enforcement-discretion windows in early 2025, a compounded tirzepatide product must not be essentially a copy of a commercially available approved drug. That generally requires a prescriber-documented, patient-specific clinical difference.
Does adding B12 automatically make the formulation "not a copy"?
No. The essentially-a-copy analysis turns on whether the prescriber determined that the modification produces a significant clinical difference for the individual patient. Adding cyanocobalamin as a routine practice, without individualized justification, does not resolve the copy question — and FDA has specifically noted that the clinical rationale for such additives has not been established at a population level.
What should the prescriber document?
At minimum, the patient-specific clinical reason the compounded combination is being prescribed instead of an FDA-approved tirzepatide product, recorded in the chart and communicated on or with the prescription. Many pharmacies will request this documentation before dispensing.
What happens if FDA finalizes the 503B bulks-list exclusion?
If the May 2026 proposal is finalized as written, 503B outsourcing facilities would not be able to compound tirzepatide from bulk drug substance outside of a shortage. The proposal does not directly change 503A patient-specific compounding, which would remain governed by the essentially-a-copy framework. The comment period runs through July 30, 2026, and providers should monitor the final determination.
Related Reading
- See where tirzepatide with B12 ranks among the most-prescribed compounded medications
- Compounded tirzepatide with pyridoxine (B6)
- Compounded tirzepatide with L-carnitine
Sources
- FDA, Declaratory Order: Resolution of Shortages of Tirzepatide Injection (December 19, 2024)
- FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- FDA, FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
- FDA, FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- Federal Register, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (May 1, 2026)
- Federal Register, Extension of Comment Period (June 26, 2026)
- FDA, Understanding the Risks of Compounded Drugs
